Research ExplorerScientific StaffKatja Weisel Publications

Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations
Affiliations
1 - 150 out of 244Page size: 150

Publications

  1. 2024

  2. Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

    Salwender, H., Weinhold, N., Benner, A., Miah, K., Merz, M., Haenel, M., Jehn, C., Mai, E., Menis, E., Blau, I., Scheid, C., Hose, D., Seckinger, A., Luntz, S., Besemer, B., Munder, M., Brossart, P., Glass, B., Lindemann, H-W., Weisel, K., Hanoun, C., Schnitzler, P., Klemm, S., Goldschmidt, H., Raab, M. & Elmaagacli, A., 12.2024, In: HEMATOLOGY. 29, 1, p. 2320006

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    Rodriguez-Otero, P., Usmani, S., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X., Pérez-Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M. V., Einsele, H., Minnema, M., Cavo, M., Derman, B. A., Puig, N., Gay, F., Ho, P. J., Chng, W-J., Kastritis, E., Gahrton, G., Weisel, K., Nagarajan, C., Schjesvold, F., Mikhael, J., Costa, L., Raje, N. S., Zamagni, E., Hájek, R., Weinhold, N., Yong, K., Ye, J. C., Sidhana, S., Merlini, G., Martin, T., Lin, Y., Chari, A., Popat, R., Kaufman, J. L. & International Myeloma Working Group, 05.2024, In: LANCET ONCOL. 25, 5, p. e205-e216

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  4. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Einsele, H., Moreau, P., Bahlis, N., Bhutani, M., Vincent, L., Karlin, L., Perrot, A., Goldschmidt, H., van de Donk, N. W. C. J., Ocio, E. M., Martinez-Lopez, J., Rodríguez-Otero, P., Dytfeld, D., Diels, J., Strulev, V., Haddad, I., Renaud, T., Ammann, E., Cabrieto, J., Perualila, N., Gan, R., Zhang, Y., Parekh, T., Albrecht, C., Weisel, K. & Mateos, M-V., 04.2024, In: ADV THER. 41, 4, p. 1576-1593 18 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report

    Cords, L., Schaefers, C., Kamili, A., Hoffmann, C., Cichutek, S., Haag, F., Polywka, S., Bokemeyer, C., Leypoldt, L. B., Alsdorf, W., Schulze zur Wiesch, J. & Weisel, K. C., 28.03.2024, In: HAEMATOLOGICA.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

    Mai, E. K., Goldschmid, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., Krzykalla, J., Fenk, R., Schlenzka, J., Munder, M., Dürig, J., Blau, I. W., Huhn, S., Hose, D., Jauch, A., Kunz, C., Mann, C., Weinhold, N., Scheid, C., Schroers, R., von Metzler, I., Schieferdecker, A., Thomalla, J., Reimer, P., Mahlberg, R., Graeven, U., Kremers, S., Martens, U. M., Kunz, C., Hensel, M., Benner, A., Seidel-Glätzer, A., Weisel, K. C., Raab, M. S., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators, 02.2024, In: LANCET HAEMATOL. 11, 2, p. e101-e113

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

    Leypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., Ko, Y-D., de Wit, M., Salwender, H., Scheid, C., Graeven, U., Peceny, R., Staib, P., Dieing, A., Einsele, H., Jauch, A., Hundemer, M., Zago, M., Požek, E., Benner, A., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 01.01.2024, In: J CLIN ONCOL. 42, 1, p. 26-37 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. 2023

  9. Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials

    Laane, E., Salek, S., Oliva, E. N., Bennink, C., Clavreul, S., Richardson, P. G., Scheid, C., Weisel, K., Ionova, T. & European Hematology Association Specialized Working Group on Quality of Life and Symptoms, 08.12.2023, In: CANCERS. 15, 24, 5764.

    Research output: SCORING: Contribution to journal › Guideline, recommendation, statement › Research › peer-review

  10. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure

    Davies, F. E., Leleu, X., Vogel, P., Dhanasiri, S., Le Nouveau, P. & Weisel, K., 11.2023, In: CL LYMPH MYELOM LEUK. 23, 11, p. 829-837.e1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J. & Weisel, K., 10.2023, In: LANCET HAEMATOL. 10, 10, p. e801-e812

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

    Leypoldt, L. B., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M. S., Nogai, A., Khandanpour, C., Runde, V., Jauch, A., Zago, M., Martus, P., Goldschmidt, H., Bokemeyer, C., Dimopoulos, M. A. & Weisel, K. C., 21.09.2023, In: CANCERS. 15, 18, 4667.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  13. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

    Avivi, I., Vesole, D. H., Davila-Valls, J., Usnarska-Zubkiewicz, L., Olszewska-Szopa, M., Milunovic, V., Baumert, B., Osękowska, B., Kopińska, A., Gentile, M., Puertas-Martinez, B., Robak, P., Crusoe, E., Rodriguez-Lobato, L. G., Gajewska, M., Varga, G., Delforge, M., Cohen, Y., Gozzetti, A., Pena, C., Shustik, C., Mikala, G., Zalac, K., Alexander, H. D., Barth, P., Weisel, K., Martínez-López, J., Waszczuk-Gajda, A., Krzystański, M. & Jurczyszyn, A., 01.09.2023, In: CANCERS. 15, 17, 4359.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    Ramasamy, K., Avet-Loiseau, H., Hveding Blimark, C., Delforge, M., Gay, F., Manier, S., Martinez-Lopez, J., Mateos, M. V., Mohty, M., van de Donk, N. W. C. J. & Weisel, K., 09.2023, In: HEMASPHERE. 7, 9, p. e942

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  15. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis

    Manier, S., Dimopoulos, M., Hulin, C., Leleu, X., Delforge, M., Weisel, K., Mouro, J., Costa, B., Sturniolo, M. & Facon, T., 09.2023, In: CL LYMPH MYELOM LEUK. 23, 9, p. e297-e306.e1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

    Mateos, M-V., Weisel, K., Martin, T., Berdeja, J. G., Jakubowiak, A., Stewart, A. K., Jagannath, S., Lin, Y., Diels, J., Ghilotti, F., Thilakarathne, P., Perualila, N. J., Cabrieto, J., Haefliger, B., Erler-Yates, N., Hague, C., Jackson, C. C., Schecter, J. M., Strulev, V., Nesheiwat, T., Pacaud, L., Einsele, H. & Moreau, P., 01.08.2023, In: HAEMATOLOGICA. 108, 8, p. 2192-2204 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  17. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Usmani, S. Z., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D. S., Weisel, K. C., Shu, X., Li, C. & Dimopoulos, M. A., 25.07.2023, In: BLOOD ADV. 7, 14, p. 3739-3748 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., Blade, J., Moreau, P., San-Miguel, J., Munshi, N., Rajkumar, S. V., Durie, B. G. M., Ludwig, H., Terpos, E. & International Myeloma Working Group, 07.2023, In: LANCET ONCOL. 24, 7, p. e293-e311

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  19. What do hematologists and oncologists consider necessary for their career?: Results of an online survey in Germany, Austria and Switzerland

    Giesler, M., Busson-Spielberger, M., Miemietz, B., de Wit, M., Weisel, K. & Lüftner, D., 07.2023, In: J CANCER RES CLIN. 149, 8, p. 5331-5344 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Ludwig, H., Terpos, E., van de Donk, N., Mateos, M-V., Moreau, P., Dimopoulos, M-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., Weisel, K., Broijl, A., Beksac, M., Bila, J., Schjesvold, F., Cavo, M., Hajek, R., Touzeau, C., Boccadoro, M. & Sonneveld, P., 06.2023, In: LANCET ONCOL. 24, 6, p. e255-e269

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  21. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

    Moreau, P., van de Donk, N. W. C. J., Delforge, M., Einsele, H., De Stefano, V., Perrot, A., Besemer, B., Pawlyn, C., Karlin, L., Manier, S., Leleu, X., Weisel, K., Ghilotti, F., Diels, J., Elsada, A., Morano, R., Strulev, V., Pei, L., Kobos, R., Smit, J., Slavcev, M. & Mateos, M-V., 05.2023, In: ADV THER. 40, 5, p. 2412-2425 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

    Mateos, M-V., Chari, A., Usmani, S. Z., Goldschmidt, H., Weisel, K., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Marshall, A., Slavcev, M. & Moreau, P., 05.2023, In: CL LYMPH MYELOM LEUK. 23, 5, p. 385-393 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma

    Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., Khandanpour, C., Seidel-Glaetzer, A., Trautmann-Grill, K., Kortüm, K. M., Müller-Tidow, C., Mechtersheimer, G., Goeppert, B., Stenzinger, A., Weinhold, N., Goldschmidt, H., Weisel, K. C. & Raab, M. S., 06.04.2023, In: BLOOD. 141, 14, p. 1685-1690 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  24. Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - A monocentric analysis

    Schaefers, C., Paulsen, F-O., Frenzel, C., Weisel, K., Bokemeyer, C. & Seidel, C., 04.2023, In: BRIT J HAEMATOL. 201, 2, p. 222-226 5 p.

    Research output: SCORING: Contribution to journal › Short publication › Research › peer-review

  25. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., Perrot, A., Weisel, K., Raje, N., Macro, M., Frenzel, L., Leleu, X., Wang, J., Rampelbergh, R. V., Uhlar, C. M., Vermeulen, J., Duran, J., Borgsten, F. & Usmani, S. Z., 04.2023, In: FUTURE ONCOL. 19, 13, p. 887-895 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  26. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M-V., Mark, T. M., Levin, M-D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., Carey, J., Carson, R. & Spencer, A., 10.03.2023, In: J CLIN ONCOL. 41, 8, p. 1600-1609 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  27. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

    Weisel, K., Dimopoulos, M. A., San-Miguel, J., Paner, A., Engelhardt, M., Taylor, F., Lord-Bessen, J., Yip, C., Greenwood, M., Tang, J. & Cavo, M., 03.2023, In: HEMASPHERE. 7, 3, p. e843

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  28. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

    Thompson, M. A., Boccadoro, M., Leleu, X., Vela-Ojeda, J., van Rhee, F., Weisel, K. C., Rifkin, R. M., Usmani, S. Z., Hájek, R., Cook, G., Abonour, R., Armour, M., Morgan, K. E., Yeh, S-P., Costello, C. L., Berdeja, J. G., Davies, F. E., Zonder, J. A., Lee, H. C., Omel, J., Spencer, A., Terpos, E., Hungria, V. T. M., Puig, N., Fu, C., Ferrari, R. H., Ren, K., Stull, D. M. & Chari, A., 03.2023, In: CL LYMPH MYELOM LEUK. 23, 3, p. e171-e181

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  29. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

    Lee, H. C., Ramasamy, K., Weisel, K., Abonour, R., Hardin, J. W., Rifkin, R. M., Ailawadhi, S., Terebelo, H. R., Durie, B. G. M., Tang, D., Joshi, P., Liu, L., Jou, Y-M., Che, M., Hernandez, G., Narang, M., Toomey, K., Gasparetto, C., Wagner, L. I. & Jagannath, S., 02.2023, In: CL LYMPH MYELOM LEUK. 23, 2, p. 112-122 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  30. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

    Mai, E. K., Huhn, S., Miah, K., Poos, A. M., Scheid, C., Weisel, K. C., Bertsch, U., Munder, M., Berlanga, O., Hose, D., Seckinger, A., Jauch, A., Blau, I. W., Hänel, M., Salwender, H. J., Benner, A., Raab, M. S., Goldschmidt, H. & Weinhold, N., 04.01.2023, In: BLOOD CANCER J. 13, 1, p. 1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  31. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

    Ghandili, S., Alihodzic, D., Wiessner, C., Bokemeyer, C., Weisel, K. & Leypoldt, L. B., 01.2023, In: ANN HEMATOL. 102, 1, p. 117-124 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  32. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

    Rodríguez Otero, P., Towle, K., Cope, S., Caisip, C., Davies, F. E., Delforge, M., Weisel, K., Marshall, T. S., Karampampa, K., Ayers, D., Mojebi, A., Braverman, J., Farrell, J. & Dhanda, D., 2023, In: LEUKEMIA LYMPHOMA. 64, 11, p. 1864-1869 6 p.

    Research output: SCORING: Contribution to journal › Letter › Research › peer-review

  33. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

    Emde-Rajaratnam, M., Beck, S., Benes, V., Salwender, H., Bertsch, U., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Maes, K., De Bruyne, E., Menu, E., De Veirman, K., Moreaux, J., Vanderkerken, K., Seckinger, A. & Hose, D., 2023, In: FRONT IMMUNOL. 14, p. 1286700

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. 2022

  35. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    D'Souza, A., Shah, N., Rodriguez, C., Voorhees, P. M., Weisel, K., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., Polepally, A. R., Talati, C., Lee, S., Jin, Z., Buelow, B., Vij, R. & Kumar, S., 01.11.2022, In: J CLIN ONCOL. 40, 31, p. 3576-3586 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  36. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Weinhold, N., Huhn, S., Kriegsmann, K., Luntz, S. P., Holderried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C. & German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators, 11.2022, In: LANCET HAEMATOL. 9, 11, p. e810-e821

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  37. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., Abdallah, A-O., Badros, A. Z., Knop, S., Stadtmauer, E. A., Cheng, Y., Amatangelo, M., Chen, M., Nguyen, T. V., Amin, A., Peluso, T. & van de Donk, N. W. C. J., 11.2022, In: LANCET HAEMATOL. 9, 11, p. e822-e832

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  38. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

    Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M-S., Scheid, C., Schecter, J. M., de Braganca, K. C., Varsos, H., Yeh, T-M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M. & Cohen, Y. C., 01.10.2022, In: CL LYMPH MYELOM LEUK. 22, Suppl 2, S411.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  39. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

    Leleu, X., Martin, T., Weisel, K., Schjesvold, F., Iida, S., Malavasi, F., Manier, S., Chang-Ki Min, Ocio, E. M., Pawlyn, C., Perrot, A., Quach, H., Richter, J., Spicka, I., Yong, K. & Richardson, P. G., 10.2022, In: ANN HEMATOL. 101, 10, p. 2123-2137 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  40. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Costa, L. J., Hari, P., Berdeja, J. G., De Stefano, V., Gay, F., Hooper, B., Bartlett, M., Haltner, A., Rosta, E., Kumar, S., Martin, T., Mateos, M-V., Moreau, P., Usmani, S. Z., Olyslager, Y., Schecter, J. M., Roccia, T., Garrett, A., Lee, S., Nesheiwat, T., Pacaud, L., Zhou, C., Samjoo, I. A., Lin, Y., Diels, J., Valluri, S. & Weisel, K., 10.2022, In: CURR MED RES OPIN. 38, 10, p. 1759-1767 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

    Weisel, K., Wadlund, A. O., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N. & Rodriguez-Otero, P., 10.2022, In: EUR J HAEMATOL. 109, 4, p. 388-397 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  42. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Weisel, K., Krishnan, A., Schecter, J. M., Vogel, M., Jackson, C. C., Deraedt, W., Yeh, T-M., Banerjee, A., Yalniz, F., Nesheiwat, T., Van Sanden, S., Diels, J., Valluri, S., Usmani, S. Z., Berdeja, J. G., Jagannath, S. & Martin, T., 09.2022, In: CL LYMPH MYELOM LEUK. 22, 9, p. 690-701 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  43. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

    Landgren, O., Weisel, K., Rosinol, L., Touzeau, C., Turgut, M., Hajek, R., Mollee, P., Kim, J. S., Shu, N., Hu, X., Li, C. & Usmani, S. Z., 09.2022, In: BRIT J HAEMATOL. 198, 6, p. 988-993 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  44. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

    Weisel, K., Nooka, A. K., Terpos, E., Spencer, A., Goldschmidt, H., Dirnberger, F., DeCosta, L., Yusuf, A. & Kumar, S., 08.2022, In: LEUKEMIA LYMPHOMA. 63, 8, p. 1887-1896 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  45. COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress

    Modemann, F., Ghandili, S., Schmiedel, S., Weisel, K., Bokemeyer, C. & Fiedler, W., 29.07.2022, In: CANCERS. 14, 15, 3711.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  46. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., Orlowski, R. Z., Landgren, C. O., Gay, F., Caers, J., Chng, W. J., Chari, A., Walker, B. A., Kumar, S. K., Costa, L. J., Anderson, K. C. & Morgan, G. J., 06.07.2022, In: BLOOD CANCER DISCOV. 3, 4, p. 273-284 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  47. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study

    Schönlein, M., Wrage, V., Ghandili, S., Mellinghoff, S. C., Brehm, T. T., Leypoldt, L. B., Utz, N., Schrader, R. M., Alsdorf, W., Börschel, N., Bußmann, L., Schönrock, M., Perlick, D., Schön, G., Verpoort, K., Lütgehetmann, M., Schulze Zur Wiesch, J., Weisel, K. C., Bokemeyer, C., Schafhausen, P. & Sinn, M., 13.06.2022, In: CANCER CELL. 40, 6, p. 581-583 3 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  48. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  49. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Mateos, M-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J. M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H. & Moreau, P., 05.2022, In: LEUKEMIA. 36, 5, p. 1371-1376 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  50. Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

    Piechotta, V., Skoetz, N., Engelhardt, M., Einsele, H., Goldschmidt, H., Scheid, C. & guideline group, 08.04.2022, In: DTSCH ARZTEBL INT. 119, 14, p. 253-260 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  51. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

    Facon, T., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., Goldschmidt, H., Quach, H., Mohty, M., Venner, C. P., Weisel, K., Raje, N., Hebraud, B., Belhadj-Merzoug, K., Benboubker, L., Decaux, O., Manier, S., Caillot, D., Ukropec, J., Pei, H., Van Rampelbergh, R., Uhlar, C. M., Kobos, R. & Zweegman, S., 04.2022, In: LEUKEMIA. 36, 4, p. 1066-1077 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  52. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies

    Modemann, F., Niederwieser, C., Weisel, K., Bokemeyer, C., Fiedler, W. & Ghandili, S., 03.2022, In: LEUKEMIA LYMPHOMA. 63, 3, p. 664-671 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  53. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

    Leypoldt, L. B., Besemer, B., Asemissen, A. M., Hänel, M., Blau, I. W., Görner, M., Ko, Y-D., Reinhardt, H. C., Staib, P., Mann, C., Lutz, R., Munder, M., Graeven, U., Peceny, R., Salwender, H., Jauch, A., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 03.2022, In: LEUKEMIA. 36, 3, p. 885-888 4 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  54. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

    Cavo, M., San-Miguel, J. F. F., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A. A., Avet-Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V. T. D. M., Moreau, P., Mateos, M. V., Perrot, A., Iida, S., Facon, T., Kumar, S. K., van de Donk, N. W. C. J., Sonneveld, P., Spencer, A., Krevvata, M., Heuck, C., Wang, J., Ukropec, J., Kobos, R., Sun, S., Qi, M. & Munshi, N. C., 10.02.2022, In: BLOOD. 139, 6, p. 835-844 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  55. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

    Martin, T., Krishnan, A., Yong, K., Weisel, K., Mehra, M., Nair, S., Qi, K., Londhe, A., Diels, J., Crivera, C., Jackson, C. C., Olyslager, Y., Vogel, M., Schecter, J. M., Banerjee, A., Valluri, S., Usmani, S. Z., Berdeja, J. G. & Jagannath, S., 02.2022, In: EJHaem. 3, 1, p. 97-108 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  56. MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma

    Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K. C., Scheid, C., Keller, U., Hose, D. & Bassermann, F., 25.01.2022, In: BLOOD ADV. 6, 2, p. 515-520 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  57. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

    Weisel, K., Martin, T., Krishnan, A., Jagannath, S., Londhe, A., Nair, S., Diels, J., Vogel, M., Schecter, J. M., Banerjee, A., Berdeja, J. G., Nesheiwat, T., Garrett, A., Qi, K., Valluri, S., Usmani, S. Z. & Yong, K., 01.2022, In: CLIN DRUG INVEST. 42, 1, p. 29-41 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  58. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

    Richardson, P. G., Schjesvold, F., Weisel, K., Moreau, P., Anderson, L. D., White, D., Rodriguez-Otero, P., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Beksac, M., Oriol, A., Lindsay, J., Liberati, A. M., Galli, M., Robak, P., Larocca, A., Yagci, M., Vural, F., Kanate, A. S., Jiang, R., Grote, L., Peluso, T. & Dimopoulos, M., 01.2022, In: EUR J HAEMATOL. 108, 1, p. 73-83 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  59. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

    Pape, L. J., Hambach, J., Gebhardt, A. J., Rissiek, B., Stähler, T., Tode, N., Khan, C., Weisel, K., Adam, G., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 1010270.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  60. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

    Hambach, J., Fumey, W., Stähler, T., Gebhardt, A. J., Adam, G., Weisel, K., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 838406.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  61. Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

    Krohn, S., Boje, A. S., Gehlert, C. L., Lutz, S., Darzentas, N., Knecht, H., Herrmann, D., Brüggemann, M., Scheidig, A. J., Weisel, K., Gramatzki, M., Peipp, M. & Klausz, K., 2022, In: FRONT IMMUNOL. 13, 908093.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  62. 2021

  63. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Sonneveld, P., Facon, T., San-Miguel, J., Avet-Loiseau, H., Mohty, M., Mateos, M-V., Moreau, P., Cavo, M., Pawlyn, C., Zweegman, S., Engelhardt, M., Driessen, C., Cook, G., Dimopoulos, M. A., Gay, F., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Schreder, M., Abildgaard, N., Hajek, R., Zojer, N., Kastritis, E., Broijl, A., Schjesvold, F., Boccadoro, M. & Terpos, E., 12.2021, In: LANCET HAEMATOL. 8, 12, p. e934-e946

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  64. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

    Siegel, D., Weisel, K., Zahlten-Kumeli, A., Medhekar, R., Ding, B. & Leleu, X., 12.2021, In: LEUKEMIA LYMPHOMA. 62, 12, p. 3002-3010 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  65. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma

    Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Wiesch, J. S. Z., Bokemeyer, C., Sinn, M., Weisel, K. C. & Leypoldt, L., 24.11.2021, In: J CLIN MED. 10, 23, 5499.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  66. Current Treatment Approaches to Newly Diagnosed Multiple Myeloma

    Ghandili, S., Weisel, K. C., Bokemeyer, C. & Leypoldt, L. B., 16.11.2021, In: ONCOL RES TREAT. 44, 12, p. 690-699 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  67. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

    Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Sborov, D., Suvannasankha, A., Weisel, K., Voorhees, P. M., Womersley, L., Baron, J., Piontek, T., Lewis, E., Opalinska, J., Gupta, I. & Cohen, A. D., 15.11.2021, In: CANCER-AM CANCER SOC. 127, 22, p. 4198-4212 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  68. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

    Brauneck, F., Weimer, P., Schulze zur Wiesch, J., Weisel, K. C., Leypoldt, L. B., Vohwinkel, G., Fritzsche, B., Bokemeyer, C., Wellbrock, J. & Fiedler, W., 08.11.2021, In: FRONT MED-LAUSANNE. 8, p. 763773 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  69. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Tromp, B., Delioukina, M., Vermeulen, J. & Usmani, S. Z., 11.2021, In: LANCET ONCOL. 22, 11, p. 1582-1596 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  70. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

    Salwender, H., Elmaagacli, A., Merz, M., Miah, K., Benner, A., Haenel, M., Jehn, C., Mai, E. K., Bertsch, U., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Raab, M. S., Luntz, S. P., Besemer, B., Munder, M., Brossart, P., Fuhrmann, S., Lindemann, H-W., Weisel, K., Duerig, J. & Goldschmidt, H., 10.2021, In: LEUKEMIA. 35, 10, p. 3007-3011 5 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  71. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

    Rodriguez-Otero, P., Ayers, D., Cope, S., Davies, F. E., Delforge, M., Mojebi, A., Jansen, J. P., Weisel, K., Hege, K. & Dhanasiri, S., 10.2021, In: LEUKEMIA LYMPHOMA. 62, 10, p. 2482-2491 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  72. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

    Klein, E-M., Tichy, D., Salwender, H. J., Mai, E. K., Duerig, J., Weisel, K. C., Benner, A., Bertsch, U., Akhavanpoor, M., Besemer, B., Munder, M., Lindemann, H-W., Hose, D., Seckinger, A., Luntz, S., Jauch, A., Elmaagacli, A., Fuhrmann, S., Brossart, P., Goerner, M., Bernhard, H., Raab, M. S., Blau, I. W., Haenel, M., Scheid, C., Goldschmidt, H. & On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg, 28.09.2021, In: CANCERS. 13, 19, p. 4856

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  73. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

    Ramasamy, K., Gay, F., Weisel, K., Zweegman, S., Mateos, M. V. & Richardson, P., 09.2021, In: Blood reviews. 49, p. 100808

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  74. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

    Davies, F., Rifkin, R., Costello, C., Morgan, G., Usmani, S., Abonour, R., Palumbo, A., Romanus, D., Hajek, R., Terpos, E., Cherepanov, D., Stull, D. M., Huang, H., Leleu, X., Berdeja, J., Lee, H. C., Weisel, K., Thompson, M., Boccadoro, M., Zonder, J., Cook, G., Puig, N., Vela-Ojeda, J., Farrelly, E., Raju, A., Blazer, M. & Chari, A., 09.2021, In: ANN HEMATOL. 100, 9, p. 2325-2337 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  75. Selective elimination of immunosuppressive T cells in patients with multiple myeloma

    Awwad, M. H. S., Mahmoud, A., Bruns, H., Echchannaoui, H., Kriegsmann, K., Lutz, R., Raab, M. S., Bertsch, U., Munder, M., Jauch, A., Weisel, K., Maier, B., Weinhold, N., Salwender, H. J., Eckstein, V., Hänel, M., Fenk, R., Dürig, J., Brors, B., Benner, A., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 09.2021, In: LEUKEMIA. 35, 9, p. 2602-2615 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  76. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

    Quach, H., Nooka, A., Samoylova, O., Venner, C. P., Kim, K., Facon, T., Spencer, A., Usmani, S. Z., Grosicki, S., Suzuki, K., Delimpasi, S., Weisel, K., Obreja, M., Zahlten-Kumeli, A. & Mateos, M-V., 08.2021, In: BRIT J HAEMATOL. 194, 4, p. 784-788 5 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  77. Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

    Ghandili, S., Schönlein, M., Lütgehetmann, M., Wiesch, J. S. Z., Becher, H., Bokemeyer, C., Sinn, M., Weisel, K. C. & Leypoldt, L. B., 28.07.2021, In: CANCERS. 13, 15, 3800.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  78. Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation

    Thiele, B., Binder, M., Schliffke, S., Frenzel, C., Dierlamm, J., Wass, M., Weisel, K. C., Bokemeyer, C. & Janjetovic, S., 21.07.2021, In: ONCOL RES TREAT. 44, 7-8, p. 375-381 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  79. 56/m mit Rückenschmerzen und Konzentrationsstörungen

    Leypoldt, L. B. & Weisel, K. C., 12.07.2021, In: ONKOLOGE. 2021, 27 supplement issue 1, p. 27-32

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Education

  80. Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma

    Hájek, R., Minařík, J., Straub, J., Pour, L., Jungova, A., Berdeja, J. G., Boccadoro, M., Brozova, L., Spencer, A., Rhee, F. V., Vela-Ojeda, J., Thompson, M. A., Abonour, R., Chari, A., Cook, G., Costello, C. L., Davies, F. E., Hungria, V. T., Lee, H. C., Leleu, X., Puig, N., Rifkin, R. M., Terpos, E., Usmani, S. Z., Weisel, K. C., Zonder, J. A., Bařinová, M., Kuhn, M., Šilar, J., Čápková, L., Galvez, K., Lu, J., Elliott, J., Stull, D. M., Ren, K. & Maisnar, V., 07.2021, In: FUTURE ONCOL. 17, 19, p. 2499-2512 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  81. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Nooka, A. K., Weisel, K., van de Donk, N. W., Routledge, D., Otero, P. R., Song, K., Quach, H., Callander, N., Minnema, M. C., Trudel, S., Jackson, N. A., Ahlers, C. M., Im, E., Cheng, S., Smith, L., Hareth, N., Ferron-Brady, G., Brouch, M., de Oca, R. M., Paul, S., Holkova, B., Gupta, I., Kremer, B. E. & Richardson, P., 06.2021, In: FUTURE ONCOL. 17, 16, p. 1987-2003 17 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  82. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

    Weisel, K., Mateos, M-V., Gay, F., Delforge, M., Cook, G., Szabo, Z., Desgraz, R., DeCosta, L. & Moreau, P., 06.2021, In: LEUKEMIA. 35, 6, p. 1732-1744 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  83. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Dimopoulos, M., Weisel, K., Moreau, P., Anderson, L. D., White, D., San-Miguel, J., Sonneveld, P., Engelhardt, M., Jenner, M., Corso, A., Dürig, J., Pavic, M., Salomo, M., Casal, E., Srinivasan, S., Yu, X., Nguyen, T. V., Biyukov, T., Peluso, T. & Richardson, P., 06.2021, In: LEUKEMIA. 35, 6, p. 1722-1731 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  84. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

    Hungria, V., Beksac, M., Weisel, K. C., Nooka, A. K., Masszi, T., Spicka, I., Munder, M., Mateos, M-V., Mark, T. M., Qi, M., Qin, X., Fastenau, J., Spencer, A., Sonneveld, P., Garvin, W., Renaud, T. & Gries, K. S., 05.2021, In: BRIT J HAEMATOL. 193, 3, p. 561-569 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  85. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

    Avet-Loiseau, H., San-Miguel, J., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A., Moreau, P., Plesner, T., Weisel, K., Ukropec, J., Chiu, C., Trivedi, S., Amin, H., Krevvata, M., Ramaswami, P., Qin, X., Qi, M., Sun, S., Qi, M., Kobos, R. & Bahlis, N. J., 01.04.2021, In: J CLIN ONCOL. 39, 10, p. 1139-1149 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  86. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

    Goldschmidt, H., Baertsch, M-A., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M-S., Hillengass, J., Sauer, S., Müller-Tidow, C., Luntz, S., Jauch, A., Hose, D., Seckinger, A., Brossart, P., Goerner, M., Klein, S., Schmidt-Hieber, M., Reimer, P., Graeven, U., Fenk, R., Haenel, M., Martin, H., Lindemann, H. W., Scheid, C., Nogai, A., Salwender, H., Noppeney, R., Besemer, B., Weisel, K. & German Myeloma Multicenter Group (GMMG), 04.2021, In: LEUKEMIA. 35, 4, p. 1134-1144 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  87. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

    Radocha, J., van de Donk, N. W. C. J. & Weisel, K., 29.03.2021, In: CANCERS. 13, 7, p. 1551

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  88. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

    Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H-W., Merz, M., Hose, D., Jauch, A., Seckinger, A., Luntz, S., Sauer, S., Fuhrmann, S., Brossart, P., Elmaagacli, A., Goerner, M., Bernhard, H., Hoffmann, M., Raab, M. S., Blau, I. W., Hänel, M., Benner, A., Salwender, H. J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 03.2021, In: LEUKEMIA. 35, 3, p. 809-822 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  89. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, B. G. M., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., Cavo, M., Kristinsson, S. Y., Lentzsch, S., Hajek, R., Anderson, K. C., João, C., Einsele, H., Sonneveld, P., Engelhardt, M., Fonseca, R., Vangsted, A., Weisel, K., Baz, R., Hungria, V., Berdeja, J. G., Leal da Costa, F., Maiolino, A., Waage, A., Vesole, D. H., Ocio, E. M., Quach, H., Driessen, C., Bladé, J., Leleu, X., Riva, E., Bergsagel, P. L., Hou, J., Chng, W. J., Mellqvist, U-H., Dytfeld, D., Harousseau, J-L., Goldschmidt, H., Laubach, J., Munshi, N. C., Gay, F., Beksac, M., Costa, L. J., Kaiser, M., Hari, P., Boccadoro, M., Usmani, S. Z., Zweegman, S., Holstein, S., Harrison, S., Nahi, H., Cook, G., Mateos, M-V., Rajkumar, S. V., Dimopoulos, M. A. & Richardson, P. G., 03.2021, In: LANCET ONCOL. 22, 3, p. e105-e118

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  90. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K. & San-Miguel, J., 25.02.2021, In: NEW ENGL J MED. 384, 8, p. 705-716 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  91. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

    Terpos, E., Mikhael, J., Hajek, R., Chari, A., Zweegman, S., Lee, H. C., Mateos, M-V., Larocca, A., Ramasamy, K., Kaiser, M., Cook, G., Weisel, K. C., Costello, C. L., Elliott, J., Palumbo, A. & Usmani, S. Z., 18.02.2021, In: BLOOD CANCER J. 11, 2, p. 40

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  92. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

    Chari, A., Munder, M., Weisel, K., Jenner, M., Bygrave, C., Petrucci, M. T., Boccadoro, M., Cavo, M., van de Donk, N. W. C. J., Turgut, M., Demirkan, F., Karadogan, I., Libby, E., Kleiman, R., Kuppens, S., Bandekar, R., Neff, T., Heuck, C., Qi, M., Clemens, P. L. & Goldschmidt, H., 02.2021, In: ADV THER. 38, 2, p. 1328-1341 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  93. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

    Moreau, P., Hebraud, B., Facon, T., Leleu, X., Hulin, C., Hashim, M., Hu, Y., Caillot, D., Benboubker, L., Zweegman, S., Merz, M., Weisel, K., Salwender, H., Mai, E. K., Goldschmidt, H., Bertsch, U., Vanquickelberghe, V., Kampfenkel, T., Boer, C. D., Krotneva, S., Proskorovsky, I., He, J., Lam, A., Lee, C., Cote, S. & Sonneveld, P., 02.2021, In: IMMUNOTHERAPY-UK. 13, 2, p. 143-154 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  94. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

    Perrot, A., Facon, T., Plesner, T., Usmani, S. Z., Kumar, S., Bahlis, N. J., Hulin, C., Orlowski, R. Z., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., He, J., Ho, K. F., Van Rampelbergh, R., Uhlar, C. M., Wang, J., Kobos, R., Gries, K. S., Fastenau, J. & Weisel, K., 20.01.2021, In: J CLIN ONCOL. 39, 3, p. 227-237 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  95. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

    Baertsch, M-A., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., Fuhrmann, S., Dührsen, U., Brossart, P., Neben, K., Schlenzka, J., Kunz, C., Raab, M. S., Hillengaß, J., Jauch, A., Seckinger, A., Hose, D., Luntz, S., Sonneveld, P., Lokhorst, H., Martin, H., Goerner, M., Hoffmann, M., Lindemann, H-W., Bernhard, H., Blau, I. W., Scheid, C., Besemer, B., Weisel, K. C., Hänel, M., Dürig, J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 07.01.2021, In: BLOOD CANCER J. 11, 1, p. 1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  96. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Boccadoro, M., Moreau, P., San-Miguel, J., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T., Driessen, C., Hajek, R., Dimopoulos, M. A., Gay, F., Avet-Loiseau, H., Terpos, E., Zojer, N., Mohty, M., Mateos, M-V., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., Engelhardt, M., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Abildgaard, N., Bringhen, S. & Sonneveld, P., 01.2021, In: LEUKEMIA. 35, 1, p. 31-44 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  97. 2020

  98. Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients

    Ghandili, S., Pfefferle, S., Roedl, K., Sonnemann, P., Karagiannis, P., Boenisch, O., Kluge, S., Schmiedel, S., Ittrich, H., Rohde, H., Lütgehetmann, M., Weisel, K., Bokemeyer, C., Wichmann, D., Fiedler, W., Jarczak, D. & Modemann, F., 08.12.2020, In: Blood Adv. 4, 23, p. 5936-5941 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  99. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

    Facon, T., Niesvizky, R., Mateos, M-V., Siegel, D., Rosenbaum, C., Bringhen, S., Weisel, K., Ho, P. J., Ludwig, H., Kumar, S., Wang, K., Obreja, M., Yang, Z., Klippel, Z., Mezzi, K., Goldrick, A., Tekle, C. & Dimopoulos, M. A., 10.11.2020, In: BLOOD ADV. 4, 21, p. 5449-5459 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  100. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset

    Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K. L., Hungria, V. T. D. M., Engelhardt, M., Gay, F., Garcia-Feria, A., Oliva, S., Oostvogels, R., Gozzetti, A., Rosenbaum, C. A., Kumar, S. K., Stadtmauer, E., Einsele, H., Beksac, M., Weisel, K. C., Anderson, K. C., Mateos, M-V., Moreau, P., San Miguel, J., Munshi, N. C. & Avet-Loiseau, H., 06.11.2020, In: BLOOD.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  101. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

    Goldschmidt, H., Dimopoulos, M. A., Rajkumar, S. V., Weisel, K. C., Moreau, P., Chng, W-J., Mikala, G., Cavo, M., Ramasamy, K., Suryanarayan, K., Teng, Z., Labotka, R. & Mateos, M. V., 11.2020, In: LEUKEMIA. 34, 11, p. 3019-3027 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  102. Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

    Yan, X., Xu, X. S., Weisel, K. C., Mateos, M-V., Sonneveld, P., Dimopoulos, M. A., Usmani, S. Z., Bahlis, N. J., Puchalski, T., Ukropec, J., Bellew, K., Ming, Q., Sun, S. & Zhou, H., 11.2020, In: CTS-CLIN TRANSL SCI. 13, 6, p. 1345-1354 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  103. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

    Jansen, L., Merz, M., Engelhardt, M., Weisel, K., Scheid, C., Straka, C., Langer, C., Salwender, H., Einsele, H., Kröger, N., Beelen, D. W., Dreger, P., Goldschmidt, H., Brenner, H. & German National Registry for Stem Cell Transplants (DRST), 10.2020, In: LEUKEMIA LYMPHOMA. 61, 10, p. 2365-2374 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  104. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Weisel, K., San-Miguel, J., Shpilberg, O., Grosicki, S., Špička, I., Walter-Croneck, A., Magen, H., Mateos, M-V., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Matsumoto, M., Wu, K. L., Anderson, K. C., Jou, Y-M., Ganetsky, A., Singhal, A. K. & Richardson, P. G., 04.09.2020, In: BLOOD CANCER J. 10, 9, p. 91

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  105. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

    Gavriatopoulou, M., Chari, A., Chen, C., Bahlis, N., Vogl, D. T., Jakubowiak, A., Dingli, D., Cornell, R. F., Hofmeister, C. C., Siegel, D., Berdeja, J. G., Reece, D., White, D., Lentzsch, S., Gasparetto, C., Huff, C. A., Jagannath, S., Baz, R., Nooka, A. K., Richter, J., Abonour, R., Parker, T. L., Yee, A. J., Moreau, P., Lonial, S., Tuchman, S., Weisel, K. C., Mohty, M., Choquet, S., Unger, T. J., Li, K., Chai, Y., Li, L., Shah, J., Shacham, S., Kauffman, M. G. & Dimopoulos, M. A., 09.2020, In: LEUKEMIA. 34, 9, p. 2430-2440 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  106. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

    Weisel, K., Spencer, A., Lentzsch, S., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M-D., Bosi, A., Hungria, V., Cavo, M., Lee, J-J., Nooka, A., Quach, H., Munder, M., Lee, C., Barreto, W., Corradini, P., Min, C-K., Chanan-Khan, A. A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J-C., Shin, H-J., Sonneveld, P., Casneuf, T., DeAngelis, N., Amin, H., Ukropec, J., Kobos, R. & Mateos, M-V., 20.08.2020, In: J HEMATOL ONCOL. 13, 1, p. 115

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  107. Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment

    Kriegsmann, K., Hundemer, M., Hofmeister-Mielke, N., Reichert, P., Manta, C-P., Awwad, M. H. S., Sauer, S., Bertsch, U., Besemer, B., Fenk, R., Hänel, M., Munder, M., Weisel, K. C., Blau, I. W., Neubauer, A., Müller-Tidow, C., Raab, M. S., Goldschmidt, H., Huhn, S. & For The German-Speaking Myeloma Multicenter Group Gmmg, 18.08.2020, In: CANCERS. 12, 8

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  108. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

    Weisel, K., Dimopoulos, M., Moreau, P., Yagci, M., Larocca, A., Kanate, A. S., Vural, F., Cascavilla, N., Basu, S., Johnson, P., Byeff, P., Hus, M., Rodríguez-Otero, P., Muelduer, E., Anttila, P., Hayden, P. J., Krauth, M-T., Lucio, P., Ben-Yehuda, D., Mendeleeva, L., Guo, S., Yu, X., Grote, L., Biyukov, T., Dhanasiri, S. & Richardson, P., 08.2020, In: LEUKEMIA LYMPHOMA. 61, 8, p. 1850-1859 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  109. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

    Dimopoulos, M., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A. & Usmani, S. Z., 18.07.2020, In: LANCET. 396, 10245, p. 186-197 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  110. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

    Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., Lindemann, H-W., Hügle-Dörr, B., Tichy, D., Giesen, N., Hose, D., Seckinger, A., Huhn, S., Luntz, S., Jauch, A., Elmaagacli, A., Rabold, B., Fuhrmann, S., Brossart, P., Goerner, M., Bernhard, H., Hoffmann, M., Hillengass, J., Raab, M. S., Blau, I. W., Hänel, M., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG), 07.2020, In: LEUKEMIA. 34, 7, p. 1853-1865 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  111. Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis

    Karagiannis, P., Sänger, L., Alsdorf, W., Weisel, K., Fiedler, W., Kluge, S., Wichmann, D., Bokemeyer, C. & Fuhrmann, V., 24.06.2020, In: CANCERS. 12, 6, 1678.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  112. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

    Vij, R., Nath, R., Afar, D. E. H., Mateos, M. V., Berdeja, J. G., Raab, M. S., Guenther, A., Martinez-Lopez, J., Jakubowiak, A. J., Leleu, X., Weisel, K., Wong, S., Gulbranson, S., Sheridan, J. P., Reddy, A., Paiva, B., Singhal, A., San-Miguel, J. F. & Moreau, P., 15.05.2020, In: CLIN CANCER RES. 26, 10, p. 2308-2317 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  113. Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg: Report of the University Cancer Center Hamburg

    Weisel, K. C., Morgner-Miehlke, A., Petersen, C., Fiedler, W., Block, A., Schafhausen, P., Knobloch, J. K. & Bokemeyer, C., 07.05.2020, In: ONCOL RES TREAT. 43, 6, p. 307-313 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  114. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

    Raab, M. S., Engelhardt, M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Ferstl, B., Schub, N., Röllig, C., Weisel, K., Winderlich, M., Griese, J., Härtle, S., Weirather, J., Jarutat, T., Peschel, C. & Chatterjee, M., 05.2020, In: LANCET HAEMATOL. 7, 5, p. e381-e394

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  115. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Cope, S., Toor, K., Popoff, E., Fonseca, R., Landgren, O., Mateos, M-V., Weisel, K. & Jansen, J. P., 04.2020, In: VALUE HEALTH. 23, 4, p. 441-450 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  116. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

    Dimopoulos, M. A., Niesvizky, R., Weisel, K., Siegel, D. S., Hajek, R., Mateos, M-V., Cavo, M., Huang, M., Zahlten-Kumeli, A. & Moreau, P., 09.03.2020, In: BLOOD CANCER J. 10, 3, p. 35

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  117. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis

    Ramasamy, K., Dhanasiri, S., Thom, H., Buchanan, V., Robinson, S., D'Souza, V. K. & Weisel, K., 03.2020, In: LEUKEMIA LYMPHOMA. 61, 3, p. 668-679 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  118. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma

    Bilich, T., Nelde, A., Bauer, J., Walz, S., Roerden, M., Salih, H. R., Weisel, K., Besemer, B., Marcu, A., Lübke, M., Schuhmacher, J., Neidert, M. C., Rammensee, H-G., Stevanović, S. & Walz, J. S., 28.02.2020, In: BLOOD CANCER J. 10, 2, p. 24

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  119. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

    Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., Spencer, A., Huang, J. S. Y., Lu, J., Sunami, K., Iida, S., Chng, W-J., Holstein, S. A., Rocci, A., Skacel, T., Labotka, R., Palumbo, A. & Anderson, K. C., 13.02.2020, In: BLOOD CANCER J. 10, 2, p. 17

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  120. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K. M., Rodríguez-Otero, P., Usmani, S. Z., Hari, P., Baz, R., Quach, H., Moreau, P., Voorhees, P. M., Gupta, I., Hoos, A., Zhi, E., Baron, J., Piontek, T., Lewis, E., Jewell, R. C., Dettman, E. J., Popat, R., Esposti, S. D., Opalinska, J., Richardson, P. & Cohen, A. D., 02.2020, In: LANCET ONCOL. 21, 2, p. 207-221 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  121. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

    Ludwig, H., Pönisch, W., Knop, S., Egle, A., Hinke, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Rumpold, H., Pour, L., Jelinek, T., Krenosz, K. J., Meckl, A., Nolte, S., Melchardt, T., Greil, R. & Zojer, N., 02.2020, In: LEUKEMIA LYMPHOMA. 61, 2, p. 377-386 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  122. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma

    Schieferdecker, A., Hörber, S., Ums, M., Besemer, B., Bokemeyer, C., Peter, A. & Weisel, K., 09.01.2020, In: BLOOD CANCER J. 10, 1, p. 2

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  123. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

    Weisel, K., Majer, I., DeCosta, L., Oriol, A., Goldschmidt, H., Ludwig, H., Campioni, M., Szabo, Z. & Dimopoulos, M., 01.2020, In: LEUKEMIA LYMPHOMA. 61, 1, p. 37-46 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  124. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

    Weisel, K., Ludwig, H., Rieth, A., Lebioda, A. & Goldschmidt, H., 01.2020, In: QUAL LIFE RES. 29, 1, p. 69-79 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  125. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

    Mateos, M-V., Spencer, A., Nooka, A. K., Pour, L., Weisel, K., Cavo, M., Laubach, J. P., Cook, G., Iida, S., Benboubker, L., Usmani, S. Z., Yoon, S-S., Bahlis, N. J., Chiu, C., Ukropec, J., Schecter, J. M., Qin, X., O' Rourke, L. & Dimopoulos, M. A., 2020, In: HAEMATOLOGICA. 105, 2, p. 468-477 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  126. 2019

  127. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

    Mateos, M-V., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W., Corradini, P., Min, C-K., Medvedova, E., Weisel, K., Chiu, C., Schecter, J. M., Amin, H., Qin, X., Ukropec, J., Kobos, R. & Spencer, A., 09.10.2019, In: CL LYMPH MYELOM LEUK.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  128. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

    Ludwig, H., Poenisch, W., Knop, S., Egle, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Krenosz, K. J., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Melchardt, T., Greil, R. & Zojer, N., 10.2019, In: BRIT J CANCER. 121, 9, p. 751-757 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  129. Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

    Merz, M., Hielscher, T., Mai, E. K., Seckinger, A., Hose, D., Jauch, A., Sauer, S., Luntz, S., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H-W., Dürig, J., Scheid, C., Haenel, M., Weisel, K., Weber, T., Delorme, S., Goldschmidt, H. & Hillengass, J., 27.08.2019, In: BLOOD CANCER J. 9, 9, p. 71

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  130. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., Stewart, A. K., Richter, J., Vij, R., Tuchman, S., Raab, M. S., Weisel, K. C., Delforge, M., Cornell, R. F., Kaminetzky, D., Hoffman, J. E., Costa, L. J., Parker, T. L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R. L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M. G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J-R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P. G. & Jagannath, S., 22.08.2019, In: NEW ENGL J MED. 381, 8, p. 727-738 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  131. Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?

    Schieferdecker, A., Binder, M., Weisel, K. & Bokemeyer, C., 07.2019, In: DEUT MED WOCHENSCHR. 144, 14, p. 982-989 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  132. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

    Hose, D., Beck, S., Salwender, H., Emde, M., Bertsch, U., Kunz, C., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Moreaux, J. & Seckinger, A., 26.06.2019, In: J HEMATOL ONCOL. 12, 1, p. 65

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  133. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., San Miguel, J., Sunami, K., O'Gorman, P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M. & OPTIMISMM trial investigators, 06.2019, In: LANCET ONCOL. 20, 6, p. 781-794 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  134. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., Usmani, S. Z. & MAIA Trial Investigators, 30.05.2019, In: NEW ENGL J MED. 380, 22, p. 2104-2115 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  135. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

    Salwender, H., Bertsch, U., Weisel, K., Duerig, J., Kunz, C., Benner, A., Blau, I. W., Raab, M. S., Hillengass, J., Hose, D., Huhn, S., Hundemer, M., Andrulis, M., Jauch, A., Seidel-Glaetzer, A., Lindemann, H-W., Hensel, M., Fronhoffs, S., Martens, U., Hansen, T., Wattad, M., Graeven, U., Munder, M., Fenk, R., Haenel, M., Scheid, C. & Goldschmidt, H., 28.05.2019, In: BMC CANCER. 19, 1, p. 504

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  136. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

    Costello, C., Davies, F. E., Cook, G., Vela-Ojeda, J., Omel, J., Rifkin, R. M., Berdeja, J., Puig, N., Usmani, S. Z., Weisel, K., Zonder, J. A., Terpos, E., Spencer, A., Leleu, X., Boccadoro, M., Thompson, M. A., Romanus, D., Stull, D. M. & Hungria, V., 05.2019, In: FUTURE ONCOL. 15, 13, p. 1411-1428 18 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  137. Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

    Weisel, K. C., Scheid, C., Zago, M., Besemer, B., Mai, E. K., Haenel, M., Duerig, J., Munder, M., Lindemann, H-W., Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Salwender, H. & Goldschmidt, H., 08.04.2019, In: BLOOD CANCER J. 9, 4, p. 45

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  138. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

    Hutchison, C. A., Cockwell, P., Moroz, V., Bradwell, A. R., Fifer, L., Gillmore, J. D., Jesky, M. D., Storr, M., Wessels, J., Winearls, C. G., Weisel, K., Heyne, N. & Cook, M., 04.2019, In: LANCET HAEMATOL. 6, 4, p. e217-e228

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  139. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

    Holstein, S. A., Ye, J. C., Howard, A., Bhutani, M., Gormley, N., Hahn, T., Hillengass, J., Krishnan, A., Landgren, C. O., Munshi, N. C., Oliva, S., Owen, R. G., Pasquini, M. C., Puig, N., Weinhold, N., Weisel, K. & McCarthy, P. L., 03.2019, In: BIOL BLOOD MARROW TR. 25, 3, p. e89-e97

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  140. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

    Ludwig, H., Moreau, P., Dimopoulos, M. A., Mateos, M-V., Kaiser, M., Hajek, R., Feng, S., Cocks, K., Buchanan, J. & Weisel, K., 22.02.2019, In: BLOOD CANCER J. 9, 3, p. 23

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  141. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making

    Gonzalez-McQuire, S., Dimopoulos, M-A., Weisel, K., Bouwmeester, W., Hájek, R., Campioni, M., Bennison, C., Xu, W., Pantiri, K., Hensen, M., Terpos, E. & Knop, S., 08.02.2019, In: MDM POLICY PRACT. 4, 1, p. 2381468318814253

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  142. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

    Qian, X., Dimopoulos, M. A., Amatangelo, M., Bjorklund, C., Towfic, F., Flynt, E., Weisel, K. C., Ocio, E. M., Yu, X., Peluso, T., Sternas, L., Zaki, M., Moreau, P. & Thakurta, A., 02.2019, In: LEUKEMIA LYMPHOMA. 60, 2, p. 462-470 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  143. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

    Kriegsmann, K., Baertsch, M-A., Awwad, M. H. S., Merz, M., Hose, D., Seckinger, A., Jauch, A., Becker, N., Benner, A., Raab, M. S., Hillengass, J., Bertsch, U., Dürig, J., Salwender, H. J., Hänel, M., Fenk, R., Munder, M., Weisel, K., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 29.01.2019, In: BLOOD CANCER J. 9, 2, p. 13

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  144. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W-J., Kaiser, M., Zweegman, S., Mateos, M-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A. B., Gupta, N., Labotka, R., Rajkumar, S. V. & TOURMALINE-MM3 study group, 19.01.2019, In: LANCET. 393, 10168, p. 253-264 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  145. A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

    Weisel, K., Sonneveld, P., Spencer, A., Beksac, M., Rizzo, M., Xu, Y., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L. & Lam, A., 01.2019, In: LEUKEMIA LYMPHOMA. 60, 1, p. 151-162 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  146. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

    Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Dührsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Merz, M., Baertsch, M-A., Jauch, A., Hose, D., Martin, H., Lindemann, H-W., Blau, I. W., Scheid, C., Weisel, K. C., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 01.2019, In: LEUKEMIA. 33, 1, p. 258-261 4 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  147. 2018

  148. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

    Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M-D., Bosi, A., Hungria, V., Cavo, M., Lee, J-J., Nooka, A. K., Quach, H., Lee, C., Barreto, W., Corradini, P., Min, C-K., Scott, E. C., Chanan-Khan, A. A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J-C., Shin, H-J., Sonneveld, P., Soong, D., Casneuf, T., Chiu, C., Amin, H., Qi, M., Thiyagarajah, P., Sasser, A. K., Schecter, J. M. & Mateos, M-V., 12.2018, In: HAEMATOLOGICA. 103, 12, p. 2079-2087 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  149. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

    Dimopoulos, M. A., Lonial, S., Betts, K. A., Chen, C., Zichlin, M. L., Brun, A., Signorovitch, J. E., Makenbaeva, D., Mekan, S., Sy, O., Weisel, K. & Richardson, P. G., 15.10.2018, In: CANCER-AM CANCER SOC. 124, 20, p. 4032-4043 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  150. Maintenance and continuous therapy for multiple myeloma

    Richardson, P. G., Laubach, J., Gandolfi, S., Facon, T., Weisel, K. & O'Gorman, P., 08.2018, In: EXPERT REV ANTICANC. 18, 8, p. 751-764 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  151. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

    Dimopoulos, M., Weisel, K., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M-V., Ardizzoia, A., Kueenburg, E., Collins, S., Di Micco, A., Rosettani, B., Li, Y., Bacon, P. & Sonneveld, P., 10.07.2018, In: J CLIN ONCOL. 36, 20, p. 2035-2043 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  152. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

    Moreau, P., Mateos, M-V., Berenson, J. R., Weisel, K., Lazzaro, A., Song, K., Dimopoulos, M. A., Huang, M., Zahlten-Kumeli, A. & Stewart, A. K., 07.2018, In: LANCET ONCOL. 19, 7, p. 953-964 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  153. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

    Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet-Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, M. A., San-Miguel, J. F., Terpos, E., Zweegman, S., Garderet, L., Mateos, M-V., Cook, G., Leleu, X., Goldschmidt, H., Jackson, G., Kaiser, M., Weisel, K., van de Donk, N. W. C. J., Waage, A., Beksac, M., Mellqvist, U. H., Engelhardt, M., Caers, J., Driessen, C., Bladé, J. & Sonneveld, P., 07.2018, In: LEUKEMIA. 32, 7, p. 1542-1560 19 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  154. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

    Goldschmidt, H., Moreau, P., Ludwig, H., Niesvizky, R., Chng, W-J., Joshua, D., Weisel, K., Spencer, A., Orlowski, R. Z., Feng, S., Iskander, K. S. & Dimopoulos, M. A., 06.2018, In: LEUKEMIA LYMPHOMA. 59, 6, p. 1364-1374 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  155. Corrigendum to "Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography" [Eur. J. Radiol. 85 (December (12)), 2016, 2195-2199]

    Schabel, C., Horger, M., Kum, S., Weisel, K., Fritz, J., Ioanoviciu, S. D. & Bier, G., 06.2018, In: EUR J RADIOL. 103, p. 163

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  156. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

    Holstein, S. A., Avet-Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., Wallace, P. K., Weisel, K. & McCarthy, P. L., 04.2018, In: BIOL BLOOD MARROW TR. 24, 4, p. 641-648 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  157. Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma

    Horger, M., Fritz, J., Thaiss, W. M., Ditt, H., Weisel, K., Haap, M. & Kloth, C., 03.2018, In: SKELETAL RADIOL. 47, 3, p. 351-361 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Previous 1 2 Next